Suppr超能文献

利用两种不同的肝癌细胞系开发丙型肝炎病毒生产报告测定系统。

Development of hepatitis C virus production reporter-assay systems using two different hepatoma cell lines.

机构信息

Department of Tumor Virology, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8544, Japan.

Department of Virology II, National Institute of Infectious Disease, Tokyo 162-8640, Japan.

出版信息

J Gen Virol. 2012 Jul;93(Pt 7):1422-1431. doi: 10.1099/vir.0.040725-0. Epub 2012 Mar 28.

Abstract

A hepatitis C virus (HCV) infection system was developed previously using the HCV JFH-1 strain (genotype 2a) and HuH-7 cells, and this cell culture is so far the only robust production system for HCV. In patients with chronic hepatitis C, the virological effects of pegylated interferon and ribavirin therapy differ depending on the HCV strain and the genetic background of the host. Recently, we reported the hepatoma-derived Li23 cell line, in which the JFH-1 life cycle is reproduced at a level almost equal to that in HuH-7-derived RSc cells. To monitor the HCV life cycle more easily, we here developed JFH-1 reporter-assay systems using both HuH-7- and Li23-derived cell lines. To identify any genetic mutations by long-term cell culture, HCV RNAs in HuH-7 cells were amplified 130 days after infection and subjected to sequence analysis to find adaptive mutation(s) for robust virus replication. We identified two mutations, H2505Q and V2995L, in the NS5B region. V2995L but not H2505Q enhanced JFH-1 RNA replication. However, we found that H2505Q but not V2995L enhanced HCV RNA replication of strain O (genotype 1b). We also selected highly permissive D7 cells by serial subcloning of Li23 cells. The expression levels of claudin-1 and Niemann-Pick C1-like 1 in D7 cells are higher than those in parental Li23 cells. In this study, we developed HCV JFH-1 reporter-assay systems using two distinct hepatoma cell lines, HuH-7 and Li23. The mutations in NS5B resulted in different effects on strains O and JFH-1 HCV RNA replication.

摘要

先前已经建立了丙型肝炎病毒(HCV)感染系统,该系统使用 HCV JFH-1 株(基因型 2a)和 HuH-7 细胞,到目前为止,该细胞培养是唯一用于 HCV 的强大生产系统。在慢性丙型肝炎患者中,聚乙二醇化干扰素和利巴韦林治疗的病毒学效果因 HCV 株和宿主的遗传背景而异。最近,我们报道了肝癌衍生的 Li23 细胞系,其中 JFH-1 生命周期的复制水平几乎与 HuH-7 衍生的 RSc 细胞相当。为了更轻松地监测 HCV 生命周期,我们在此使用 HuH-7 和 Li23 衍生的细胞系开发了 JFH-1 报告基因测定系统。为了在长期细胞培养中鉴定任何遗传突变,我们在感染后 130 天扩增 HuH-7 细胞中的 HCV RNA,并进行序列分析以发现用于稳健病毒复制的适应性突变。我们在 NS5B 区域发现了两个突变,H2505Q 和 V2995L。V2995L 而非 H2505Q 增强了 JFH-1 RNA 复制。但是,我们发现 H2505Q 而非 V2995L 增强了 HCV O 株(基因型 1b)的 RNA 复制。我们还通过 Li23 细胞的连续亚克隆选择了高度允许的 D7 细胞。D7 细胞中 Claudin-1 和 Niemann-Pick C1-like 1 的表达水平高于亲本 Li23 细胞。在这项研究中,我们使用两种不同的肝癌细胞系 HuH-7 和 Li23 开发了 HCV JFH-1 报告基因测定系统。NS5B 中的突变对 O 和 JFH-1 HCV RNA 复制产生了不同的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验